Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 356 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... March 19, 2020 Do Black Lives Matter Less Than Those of Cancer Survivors? June 18, 2020 Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... March 21, 2022 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 Load more HOT NEWS Why the voices of people affected by cancer are critical to... Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival... Building on Success, Maximizing Opportunities: NCI’s Annual Plan & Budget Proposal
